Rate of visual field loss in progressive glaucoma.

Objective: To investigate the rate of visual field (VF) loss in progressive glaucoma.

Setting: Outpatient department, nonreferral base.

Methods: A cohort of 34 patients with normal-pressure glaucoma (NPG), 68 patients with primary open-angle glaucoma (POAG), and 125 patients with ocular hypertension (OHT) were followed up for an average of 9 years.

[Four new drugs for glaucoma: apraclonidine, brimonidine, dorzolamide and latanoprost].

Glaucoma is in most of cases initially treated with drugs, viz. beta-blocking agents, miotics, sympathicomimetics and carbonic anhydrase inhibitors. The therapy of first choice is a beta-blocking agent, but in approximately 50% of the patients treated the effect becomes inadequate with time and combination therapy is necessary.

Deterioration of visual fields in patients with glaucoma with and without optic disc hemorrhages.

Objective: To evaluate visual field deterioration in patients with glaucoma with and without optic disc hemorrhages (DHs).

Design: A prospective study at quarterly base involving annual perimetry; mean follow-up of 9 years.

Setting: Outpatient department, nonreferral basis.

Cumulative incidence of patients with disc hemorrhages in glaucoma and the effect of therapy.

Purpose: In this longitudinal study, the cumulative incidence of patients with glaucoma and disc hemorrhages was investigated. A possible effect of glaucoma therapy on the incidence rate of disc hemorrhages was evaluated.

Methods: A group consisting of 68 patients with primary open-angle glaucoma (POAG), 34 with normal-pressure glaucoma, and 125 with suspected glaucoma (mean follow-up, 7.

Effects of endotoxemia on systemic plasma loss and hematocrit in rats.

Endotoxemia in rats increases plasma extravasation but does not result in continuously rising hematocrit. These contradictory observations led us to design a study in anesthetized rats (C, control rats, n = 10; E, endotoxin rats, n = 10) in which we continuously measured in blood hematocrit (conductivity cell) and changes in concentration of 125I-HSA (human serum albumin) and 51Cr-labeled red cell (51Cr-RBC; multichannel analyzer) in an extracorporeal circuit. In two additional series of experiments we measured in blood samples changes in protein concentration (series II, C: n = 7, E: n = 7) and uptake of intraperitoneally injected 125I-HSA and 51Cr-RBC (reflecting lymph flow rate; series III, C: n = 6, E: n = 7).